文献速递淋巴瘤造血干细胞移植与细胞治疗

新型人源化CD19/BAFFR双顺反子嵌合抗原受体T细胞的开发及其对B细胞系肿瘤的强效抗肿瘤活性

Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.
PubMed 文献 · Br J Haematol · 2024-07-03

研究构建了基于人源化CD19单链可变区片段(scFv)与BAFFR重链单域抗体(VHH)的第二代4-1BB-CD3ζ双顺反子CAR-T细胞,并在体外和体内与单靶点CAR-T进行比较。双顺反子CAR-T(BI CARs)保留各自抗原结合能力,杀伤和细胞因子分泌更强,反复抗原刺激后耗竭表型更少,在小鼠异种移植模型中抗肿瘤作用更强且持久,包括对CD19或BAFFR缺陷肿瘤。

要点

  • 构建人源化CD19/BAFFR双顺反子CAR,基于4-1BB-CD3ζ二代结构。
  • BI CARs体外杀伤和IL-2、TNF-α分泌强于单靶点CAR-T。
  • BI CARs反复抗原刺激后耗竭表型更少,小鼠体内抗肿瘤更强更持久。

核心结论

  • 基于scFv与VHH组合的人源化CD19/BAFFR双顺反子CAR在体外和体内均显示强效且持久的抗肿瘤能力,包括对CD19或BAFFR缺陷的肿瘤。

研究设计与样本

  • 研究构建含人源化CD19 scFv和BAFFR VHH的第二代4-1BB-CD3ζ CAR结构,并在体外和体内功能比较不同构造的CAR-T细胞。

主要发现

  • 最佳串联和双顺反子(BI)结构保留各自抗原结合能力,靶细胞刺激下均显示特异性激活。
  • BI CAR-T细胞(BI CARs)的肿瘤杀伤能力及白细胞介素-2和肿瘤坏死因子-α分泌强于单靶点CAR-T细胞。
  • BI CARs在反复抗原刺激后耗竭表型更少,在小鼠异种移植模型中显示更强、更持久的抗肿瘤效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable efficacy in treating advanced B-cell malignancies by targeting CD19, but antigen-negative relapses and immune responses triggered by murine-derived antibodies remain significant challenges, necessitating the development of novel humanized multitarget CAR-T therapies. Here, we engineered a second-generation 4-1BB-CD3ζ-based CAR construct incorporating humanized CD19 single-chain variable fragments (scFvs) and BAFFR single-variable domains on heavy chains (VHHs), also known as nanobodies. The resultant CAR-T cells, with different constructs, were functionally compared both in vitro and in vivo. We found that the optimal tandem and bicistronic (BI) structures retained respective antigen-binding abilities, and both demonstrated specific activation when stimulated with target cells. At the same time, BI CAR-T cells (BI CARs) exhibited stronger tumour-killing ability and better secretion of interleukin-2 and tumour necrosis factor-alpha than single-target CAR-T cells. Additionally, BI CARs showed less exhaustion phenotype upon repeated antigen stimulation and demonstrated more potent and persistent antitumor effects in mouse xenograft models. Overall, we developed a novel humanized CD19/BAFFR bicistronic CAR (BI CAR) based on a combination of scFv and VHH, which showed potent and sustained antitumor ability both in vitro and in vivo, including against tumours with CD19 or BAFFR deficiencies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wu S, Luo Q, Li F, et al. Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms. Br J Haematol. 2024. PMID: 38960449. doi:10.1111/bjh.19631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。